SCHEMBL6289533

SCHEMBL6289533

COC(=O)c1ccc(C(NC(=O)Nc2cc(OC)cc(C(F)(F)F)c2)c2ccccc2C2CCCCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.43
GIPR P48546 1/20 0.43
EPHX2 P34913 3/20 0.42
ADCY8 P40145 1/20 0.40
ADCY1 Q08828 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
CCR3 P51677 3/20 0.38
NPC1 O15118 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
RHOA P61586 1/20 0.36
TMPRSS4 Q9NRS4 1/20 0.36
P2RY1 P47900 1/20 0.36
RAF1 P04049 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647986 0.94 GCGR (0.43) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL2653513 0.77 GCGR (0.70) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL2653516 0.77 GCGR (0.70) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL2646889 0.75 ALDH1A1 (0.35) EPHX2MEN1KMT2ASMN1; SMN2CCR3
SCHEMBL2646883 0.75 GCGR (0.60) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL2646134 0.75 GCGR (0.60) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL2646135 0.75 GCGR (0.60) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL4091748 0.74 GCGR (0.47) GCGRGIPREPHX2ADCY8ADCY1
SCHEMBL2646748 0.69 GCGR (0.47) GCGRGIPREPHX2MEN1KMT2A
SCHEMBL2646887 0.69 GCGR (0.78) GCGRGIPRSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953812-B2 Glucagon antagonists/inverse agonists NOVO NORDISK, INC. (DK) 2005-10-11 US disclosed
US-20040024045-A1 Glucagon antagonists/inverse agonists PFIZER INC 2004-02-05 US disclosed
US-6562807-B2 For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity NOVO NORDISK A/S (DK) 2003-05-13 US disclosed
US-20020143186-A1 Glucagon antagonists/inverse agonists PFIZER INC 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024045-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885EPHX2 3116/4885
US-20020143186-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885EPHX2 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.